Free Trial

Ardent Health Partners (ARDT) Stock Forecast & Price Target

Ardent Health Partners logo
$15.68 -0.76 (-4.62%)
(As of 11:50 AM ET)

Ardent Health Partners - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
10

Based on 12 Wall Street analysts who have issued ratings for Ardent Health Partners in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 2 have given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for ARDT.

Consensus Price Target

$21.82
39.15% Upside
According to the 12 analysts' twelve-month price targets for Ardent Health Partners, the average price target is $21.82. The highest price target for ARDT is $27.00, while the lowest price target for ARDT is $18.00. The average price target represents a forecasted upside of 39.15% from the current price of $15.68.
Get the Latest News and Ratings for ARDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ardent Health Partners and its competitors.

Sign Up

ARDT Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
N/A
Buy
8 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
N/A
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$21.82$21.91$21.70N/A
Forecasted Upside39.15% Upside13.28% Upside25.65% UpsideN/A
Consensus Rating
Buy
Buy
Buy
N/A
This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

ARDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ardent Health Partners Stock vs. The Competition

TypeArdent Health PartnersMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside32.63% Upside26,931.56% Upside9.82% Upside
News Sentiment Rating
Positive News

See Recent ARDT News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2024Royal Bank of Canada
4 of 5 stars
B. Hendrix
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$23.00 ➝ $23.00+28.56%
11/12/2024Leerink Partners
1 of 5 stars
 Boost TargetOutperform ➝ Outperform$23.00 ➝ $25.00+44.43%
11/6/2024Bank of America
4 of 5 stars
 DowngradeBuy ➝ Neutral$22.00 ➝ $19.00+5.15%
10/11/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$24.00+32.45%
9/19/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Fidel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$24.00 ➝ $24.00+37.14%
8/12/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/12/2024Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Greaves
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$18.00 ➝ $18.00+15.09%
8/12/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00+34.27%
8/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$27.00+72.63%
8/12/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$18.00+15.09%
8/12/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$20.00+27.88%
8/12/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$21.00 ➝ $21.00+34.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:10 PM ET.


ARDT Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Ardent Health Partners is $21.82, with a high forecast of $27.00 and a low forecast of $18.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardent Health Partners in the last year. There are currently 2 hold ratings, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDT shares.

According to analysts, Ardent Health Partners's stock has a predicted upside of 39.15% based on their 12-month stock forecasts.

Over the previous 90 days, Ardent Health Partners's stock had 1 upgrade and 1 downgrade by analysts.

Ardent Health Partners has been rated by research analysts at Bank of America, KeyCorp, Leerink Partners, Royal Bank of Canada, and Stephens in the past 90 days.

Analysts like Ardent Health Partners more than other "medical" companies. The consensus rating for Ardent Health Partners is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARDT compares to other companies.


This page (NYSE:ARDT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners